Leveraging rapid technological advances for human health is a global trend, driving the rise of biomedical engineering research.
Neuralink announced on social media that it received FDA breakthrough device designation for its vision-restoring Blindsight implant.
GE HealthCare (Nasdaq: GEHC)+
announced today that the FDA has cleared its new imaging tool to assess people with potential Alzheimer’s disease.
Forest Devices announced today that it received FDA 510(k) clearance for its SignalNED Model RE system for brain state analysis.
Boston Scientific (NYSE: BSX)+
announced today that it received FDA approval to expand the indication for its current-generation Ingevity+ pacing leads.
Philips (NYSE: PHG)+
announced today that it introduced the FDA-approved, 160 cm version of its LumiGuide endovascular navigation wire.
Edwards Lifesciences (NYSE: EW)+
announced that it launched its Sapien 3 transcatheter pulmonary valve implant (TPVI) system with Alterra adaptive prestent in Europe.
Medtronic (NYSE: MDT)+
today announced the publication of its novel approach to studying adaptive deep brain stimulation (aDBS).
Commercial partner Ascensia is in discussions with insulin pump manufacturers to create an automated insulin delivery system.
Biotronik announced today that it received FDA approval for its Selectra 3D catheter and Solia S lead for use in left bundle branch area pacing (LBBAP).